Diagnostic Usefulness of Interferon Gamma Release Assay for Active Tuberculosis in Immunocompromised Patients

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00962676

Enrollment

140

Registered

2009-08-20

Start date

2009-07-31

Completion date

2010-12-31

Last updated

2012-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tuberculosis

Keywords

suspicious of tuberculosis, immunocompromised patients

Brief summary

For diagnosis of active tuberculosis, interferon-γ release assay based mycobacterium tuberculosis specific antigen may show higher sensitivity than tuberculin skin test in immunocompromised patients. Therefore, interferon-γ release assay have a role as a rapid diagnostic adjunctive methods for active tuberculosis in immunocompromised patients.

Interventions

None listed

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Patient suspicious of active tuberculosis with immunocompromised condition * Immunocompromised condition patients with 1. solid cancer with chemotherapy 2. hematologic malignancy 3. organ transplantation 4. immunosuppressant 5. ESRD on renal replacement therapy 6. diabetes 7. advanced liver cirrhosis

Exclusion criteria

* Patients with 1. less than 20 years 2. who don't agree the participation of study 3. hypersensitivity history to tuberculin 4. pregnancy

Countries

South Korea

Outcome results